Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC-100880).
D000230:Adenocarcinoma / Q000188:drug therapy; D000328:Adult; D000368:Aged; D000470:Alkaloids / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy; D002277:Carcinoma / Q000188:drug therapy; D002283:Carcinoma, Bronchogenic / Q000188:drug therapy; D002855:Chromatography, Thin Layer; D002986:Clinical Trials as Topic; D003110:Colonic Neoplasms / Q000188:drug therapy; D004802:Eosinophilia / Q000139:chemically induced; D005069:Evaluation Studies as Topic; D005470:Fluorometry; D006207:Half-Life; D006394:Hemangiosarcoma / Q000188:drug therapy; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy; D007970:Leukopenia / Q000139:chemically induced; D008545:Melanoma / Q000188:drug therapy; D008654:Mesothelioma / Q000188:drug therapy; D008875:Middle Aged; D010936:Plant Extracts / Q000627:therapeutic use; D013921:Thrombocytopenia / Q000139:chemically induced
D000470:Alkaloids; D000970:Antineoplastic Agents; D010936:Plant Extracts